ATC Group: N02AE01 Buprenorphine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N02AE01 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N02 Analgesics
3 N02A Opioids
4 N02AE Oripavine derivatives
5 N02AE01 Buprenorphine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
PAREN - Parenteral 1.2 mg
SL - Sublingual 1.2 mg
T-DERMAL - Transdermal 1.2 mg

Active ingredients in N02AE01

Active Ingredient Description
Buprenorphine

Buprenorphine is an opioid partial agonist/antagonist which attaches itself to the ÎŒ (mu) and Îș (kappa) receptors of the brain. Its activity in opioid maintenance treatment is attributed to its slowly reversible link with the ÎŒ receptors which, over a prolonged period, minimises the need of illicit opioids for patients with opioid dependence.

Related product monographs

Title Information Source Document Type  
BUTEC Transdermal patch Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
BUTRANS Transdermal system FDA, National Drug Code (US) MPI, US: SPL/PLR
NORSPAN Patch Medicines and Medical Devices Safety Authority (NZ) MPI, EU: SmPC
RELETRANS Transdermal patch Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
SUBOXONE Sublingual tablet European Medicines Agency (EU) MPI, EU: SmPC
TEMGESIC Solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
TEMGESIC Sublingual tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
TRANSTEC Transdermal patch Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Australia (AU)

Brazil (BR)

Canada (CA)

Croatia (HR)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Italy (IT)

Japan (JP)

Lithuania (LT)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Tunisia (TN)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.